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Abstract
BACKGROUND: Currently, there is growing interest in the use
of the beta emitter 90Y in systemic therapy in oncology. For suc-
cessful therapy, an appropriate ligand is chosen to carry the
isotope to the place of its action. As well as performing this func-
tion, the type of the ligand influences both the course and the
side effects of the treatment. For RIT of lymphomas, bone mar-
row becomes the critical organ; in NET patients treated with
labelled somatostatin analogues, increased kidney irradiation
can occur. The aim of this study was to evaluate the side effects
of therapy using 90Y associated with different ligands, depend-
ing on the charge to critical organs after treatment in two groups
of patients: those with neuroendocrine tumours and those with
non-Hodgkin's lymphomas.
MATERIAL AND METHODS: 32 patients with histopathological-
ly confirmed NET treated with 90Y-DOTATATE  (7.4 GBq/m2 cu-
mulative dose) and  30 NHL patients treated with 90Y-ibritumom-
ab tiuxetan (1200 MBq max dose) were enrolled in the study.
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The kidney function and changes of blood indices were assessed
during the course of the therapy.
RESULTS: 59% of NET patients treated with 90Y-DOTATATE dis-
played transient reduction of blood indices, the largest after cy-
cles III and IV of therapy. After 5 months an increase in creati-
nine level was noticed, but no statistically important changes in
creatinine level and GFR were observed. In the group of pa-
tients with NHL, the change of haematological indices after RIT
concerned mainly PLT, ANC and WBC. The reduction of the
average PLT and WBC values started in the first weeks after the
treatment application, reaching nadir in the 6th week and 8th
week, respectively. No life threatening infections were observed
in either group of patients.
CONCLUSIONS: After treatment with the use of the 90Y radionu-
clide, no significant treatment toxicity, including disorders in-
volving the critical organs for both types of therapies, was found
in the groups of neuroendocrine tumour and non-Hodgkin's lym-
phoma patients.
Key words: 90Y-DOTA TATE, 90Y-ibritumomab tiuxetan,
neuroendocrine tumours, non-Hodgkin's lymphoma,
radioimmunotherapy
Introduction
Oncological diseases are still a challenge to clinicians and in-
spire the search for new diagnostic and therapeutic procedures.
Lately, radionuclide therapy with 90Y-labelled compounds has been
introduced in the treatment of neuroendocrine tumours (NET) and
non-Hodgkin's lymphomas (NHL).
The beta emitter Yttrium-90 is a radionuclide developed from
strontium-90 through beta decay. Yttrium-90 decays, with a half-
life of 2.7 days (64 hours), to stable Zirconium-90. The beta parti-
cles emitted by 90Y have a maximum energy of 2.27 MeV, which
gives a maximum range in tissue of 11.3 mm [1, 2].
Yttrium-90 was until recently administered only locally for the
purpose of radiosynovectomy and in coronary artery brachythera-
py to prevent stent restenosis [3, 4].
90Y has adequate energy to have a cell killing effect in the tu-
mour, and, in addition, the emission of only beta radiation makes
the treatment an outpatient procedure. No risk resulting from gam-
ma radiation to other individuals can be expected [1, 5].
For successful therapy, an appropriate ligand should be cho-
sen to carry the isotope to the place of its action. Ligands influ-
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ence both the course and the side effects of the treatment. Yttri-
um connected by chelating agent Tiuxetan to the monoclonal an-
tibody against antigen CD20+ expressed on the surface of type
B lymphocytes is used in non-Hodgkin's lymphoma radio-immu-
notherapy (RIT). It enables the direct action of the radiation not
only on the tumour, but also on the adjacent neoplasmatic cells
not expressing the antigens on their surface (so-called crossfire
effect). In the treatment of the NET, a somatostatin analogue la-
belled with radionuclide is used. Ligand — chelator — [DOTA,
Tyr3] octreotate complex is characterised by the greatest affinity
to somatostatin receptor type 2, which is expressed in most of
the NETs.
In the case of the application of yttrium-labelled somatosta-
tin analogues (ss) in NET, regarding the properties of the ligand
which is secreted by glomerular filtration and later reabsorbed
in proximal canaliculi, causing its retention in the interstitial area,
an increased kidney irradiation can occur [6]. Therefore, kid-
neys are the critical organs in therapy using 90Y-labelled soma-
tostatin analogues. The indications for the radioisotope NET
treatment are the presence of disseminated and/or inoperable
tumours previously demonstrating positive somatostatin recep-
tor scintigraphy (SRS). The following 90Y-labelled SS are the most
important: [DOTA, Tyr3] octreotide (DOTA TOC), DOTA-lan-
reotide (DOTA LAN) and [DOTA, Tyr3] octreotate (DOTA TATE)
[6–8].
For lymphomas, bone marrow becomes the critical organ in
the given therapy. Bone marrow toxicity depends mainly on the
degree of bone marrow infiltration (an absolute counter-indica-
tion for RIT is a bone marrow infiltration of > 25%), as well as on
the stem-cell reserve (we should expect higher toxicity in patients
with poor-cell bone marrow after failures of earlier applied proce-
dures) [9]. The recent 90Y ibritumomab tiuxetan (Zevalin) therapy
registration refers to patients suffering from relapse after treat-
ment of low degree malignancy follicular lymphoma, or in Ritux-
imab therapy primary resistance [2, 10]. The safety of the sub-
stance and the achieved outcome causes Zevalin to be more and
more frequently applied in other types of non-Hodgkin's lympho-
mas.
In those two types of tumours, different activities of 90Y are ad-
ministered. In the group of NET patients treated in our clinics, the
maximum calculated total 90Y-DOTA TATE activity reached 7.4 GBq
per 1 m2 of body surface area (BSA), given in 3 to 5 treatment
courses. To obtain nephroprotection, a protective arginine and
lysine amino acid infusion before and after the administration of
the radiolabelled SS was administered, blocking the capture of the
tracer. In the case of lymphomas, the 90Y-Zevalin was given once,
with activity not exceeding 1.2 GBq [11].
The aim of our study was to evaluate the side effects of thera-
pies using 90Y associated with two different types of ligands, in two
groups of patients: those with neuroendocrine tumours and those
with non-Hodgkin's lymphomas.
Material and methods
Thirty-two patients (19 females and 13 males) aged 37–75 years
(mean age 58.03 ± 10.75 years) with histopathologically confirmed
NET treated in the Endocrinology Department of the University
Hospital in Krakow between 2001 and 2007 were included in the
study. Twenty-nine of them were diagnosed to have disseminated
disease. In 3 patients the tumour was inoperable, in 1 subject the
primary focus was unknown (UPF). The patients with normal labo-
ratory tests: white blood cells (WBC) > 3000/ul, blood platelet lev-
el (PLT) > 100'000/ul, urea < 10 mmol/l, creatinine < 160 umol/l,
glomerular filtration rate (GFR) > 40 ml/min) and positive [99mTc-
EDDA/HYNIC]octreotate somatostatin receptor scintigraphy qual-
ified for the study.
Radioimmunotherapy (RIT) was applied in 30 patients (16
females and 14 males) aged 41–82 years (mean age 58.73 ± 11.26
years) diagnosed to have non-Hodgkin's lymphoma CD 20+ of
stage III and IV according to Ann Arbor classification. All patients
were followed-up by the Haematology Department of the Univer-
sity Hospital in Krakow. There were 16 patients with NHL and 14
patients with mantle cell lymphoma. RIT was applied either as first-
line treatment, after obtaining partial remission (PR) after first- and
second-line treatments, or upon relapse following ineffective im-
munotherapy or chemotherapy. The patients with bone-marrow
infiltration > 25%, with PLT < 100,000/µl, WBC < 2,500/µl, after
earlier radiotherapy covering > 30% of the body area, after earlier
bone-marrow allo- or auto-transplantation, with active HBV, HCV,
HIV infections, and kidney or liver failure were excluded. The pa-
tients with mantle cell lymphoma received fludarabine, cyclophos-
phamide and mitoxantrone (FCM) chemotherapy ± Rituximab in
3–6 cycles every 21 days before RIT. After 3 cycles, qualification
for further treatment took place. When the patient failed to meet
the qualification criteria (neutrophile level (ANC) < 1,500/µl or blood
platelet level (PLT) < 100,000/µl), he or she would obtain subse-
quent cycles of therapy. If the indices failed to increase after 6 cy-
cles of treatment and the CT examination failed to find tumour mass
regression (lymph nodes < 30 mm, spleen < 14 cm), RIT was not
applied.
The 90Y-DOTATATE (Research and Development IAE Radio-
isotope Centre Otwock-Świerk, Poland) administered activity of 7.4
GBq/m2 , given in 3–5 treatment cycles every 4–9 weeks, was cal-
culated for each patient, with respect to body area, assessed from
body weight and height. In the case of reduced blood indices, the
therapy was postponed by 1–2 weeks. An 8-hour infusion of Vi-
amin 18 (amino acid preparation) was applied before and after
treatment.
The 90Y-ibritumomab tiuxetan activity was calculated based
on blood platelet level and patient body weight. At the blood plate-
let level of ≥ 150,000/µl or of 100,000–150,000/µl, the patient re-
ceived 15 MBq/kg or 11 MBq/kg, respectively, with total activity
up to1200 MBq. A dose of 250 mg/m2 of Rituximab was adminis-
tered a week before RIA, as well as 4 hours before 90Y-Zevalin
injection. The labelling of the CD 20 + antibodies was performed
in the Nuclear Medicine Department (Ibritumomab “cool kit”
— antibody and tiuxetan (Yttrium chelator) manufactured by Bay-
er-Pharma-Schering (BSP), 90Y radionuclide by CIS bio Interna-
tional, Gif-sur-Yvette Cedex, France). The radiochemical purity
of the radiopharmaceutical after labelling was higher than 95% in
all cases.
The patients with NET were treated at the Nuclear Medicine
Unit of the Endocrinology Department at the University Hospital in
Krakow and at the Nuclear Medicine Department of the Medical
University in Warsaw in the period from 2003 to 2007. All of them
gave their consent prior to inclusion to the study.
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Results
Side effects of the therapy
Morphology
During the follow up of the NET patients treated with
90Y-DOTATATE, 59% of them displayed transient reduction of blood
indices. A reduction in WBC, greatest after cycles III and IV, was
observed. In 19 persons, leucocytosis was reduced by at least
Grade 1 toxicity, based on the WHO toxicity grading scale. None
of the patients displayed Grade 4 toxicity, while 3 persons displayed
Grade 3 toxicity. One patient with WBC of 1360/mm3 was adminis-
tered Neupogen in the third month after treatment application.
A reduction in average blood platelet count with respect to ini-
tial values was observed after treatment, while the average values
were maintained within the standard. Haematological toxicity grade
3 in the PLT area was found only in one patient.
A reduction of the average values of haemoglobin after subse-
quent treatment cycles was observed in some patients. The lo-
west average haemoglobin levels were found in the fourth month
after therapy application. Usually, the haemoglobin level corre-
sponded to that of mild anaemia, while serious anaemia (Grade 3)
occurred in 3 patients after the first cycle of treatment, a month
after the treatment application, and after the second cycle. Two
patients required administration of two units of red blood concen-
trate. Figures 1 and 2 present the average values of Hb, WBC and
PLT in the patients with NET before and after treatment.
In the group of patients with NHL, the change of indices after
treatment concerned mainly PLT, ANC and WBC. The reduction of
the average PLT values started in the first weeks after the treat-
ment application, reaching nadir in the sixth week after initiation of
the therapy. After 6 months, despite the fact that the average PLT
values were coming close to the lower standard boundary, the va-
lues were still lower than the initial ones. Grade 4 toxicity occurred
in 15 patients (50%) and was maintained in the majority of the pa-
tients during 2–3 weeks, while it continued for 8 weeks in one per-
son. Grade 3 occurred in 5 patients (16.6%), staying for 5 weeks in
two patients, and 11 weeks in one patient. The lowest average PLT
values that occurred in the sixth week amounted to 48,000/mm3.
Correct PLT values were maintained in 3 patients after treatment.
Twelve patients (40%) required platelet mass transfusion, due to
low PLT values and haemorrhagic diathesis symptoms.
Leucopoenia after RIT started as early as during the first week
after treatment. Nadir occurred in the eighth week (average values
of 1,680/mm3). During the subsequent 4 weeks, the average va-
lues of the WBC increased to the level of 3,890/mm3. Grade 4 to-
xicity occurred in 8 patients (26.6%) and Grade 3 in 11 patients
(36.6%). The maximum period of Grade 4 toxicity maintenance was
Figure 1. Average haemoglobin (Hb) and white blood cells (WBC) values in patients with neuroendocrine tumours (NET) before, during and after
the therapy.
Figure 2. Average blood platelet level (PLT) values in patients with neuroendocrine tumours (NET) before, during and after the therapy.
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3 weeks, while in the case of 3 patients, Grade 3 for WBC was
maintained for 5 weeks, and 10 weeks in one patient.
The neutrophile value nadir occurred in the sixth week after
the treatment application, and the average ANC values amount-
ed to 1010/mm3 at that time. After 4 weeks, the average values
of ANC increased to 1,810/mm3. Grade 4 toxicity occurred in 12
patients (40%), while grade 3 occurred in 4 patients (13.3%). In
3 patients, grade 4 toxicity was maintained for 3 weeks. In 6
patients (20%), Neupogen was applied due to leucopoenia and
granulocytopenia, while 8 patients were treated with antibiotics
due to upper respiratory tract infections. Three patients were
hospitalised due to infections (pneumonia or neutropenia with
fever). None of the patients displayed a life-threatening infec-
tion.
Grade 3 toxicity for haemoglobin affected 7 patients (23.3%),
while grade 4 occurred in one patient. The haemoglobin nadir, with
an average value of 9.77 g/dl, occurred in the eighth week after ther-
apy application. The increase of the average values to the lower
standard boundaries was present six months after the treatment
application. Ten patients (33.3%) required red blood cell transfu-
sions. Reduced Hb values were maintained during less than 2 weeks,
although in one patient they lasted 3 weeks. The Figures present the
average Hb, ANC, WBC (Figures 1, 3) and PLT (Figures 2, 4) values
in the patients with NHL before and after treatment.
Kidney function
No statistically significant difference was found in the creat-
inine values before and after treatment in either group of pa-
tients.
In the NET patient group, a reduction of the average GFR val-
ues occurred after Cycle IV of the therapy, from the initial 93.09 ml/
min to 88.6 ml/min. After 18 months, the reduction of the average
GFR to 85.06 ml/min was clearly visible, while the average value for
that point of time was calculated on the basis of 7 measurements, 4
of them showed reductions (64, 70, 72, and 86 ml/min). Figure 5
presents average creatinine values before and after treatment in
NET and NHL patients.
The creatinine level after Zevalin treatment was higher than
normal range (117 umol/l, 94 umol/l after and before the therapy,
respectively) in only one patient.
Response to treatment
In the NET patient group, disease stability occurred in 30% of
patients, partial remission in 44%, and progression after complet-
Figure 4. Average blood platelet level PLT values in the patients with non Hodgkin’s lymphoma (NHL) before and after the therapy.
Figure 3. Average haemoglobin (Hb), white blood cells (WBC) and neutrophile level (ANC) values in patients with non Hodgkin’s lymphoma (NHL)
before and after the therapy.
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ed treatment occurred in 26% of patients. The average time to pro-
gression after completed treatment was 17.7 months.
In the NHL patient group, total remission was obtained by 52%
of patients, partial remission by 14%, and progression after com-
pleted treatment occurred in 34% of patients. The average time to
progression after completed treatment was 11.5 months.
Figure 6 presents the proportions of responses to treatment in
the NHL and NET patient groups.
Discussion
 Radiotherapy toxicity is associated with the influence of ionis-
ing radiation not only on tumour cells, but also on healthy cells,
although to a lesser degree. As a result of direct irradiation affect-
ing DNA, or the indirect effect resulting from radiolysis of water and
the occurrence of free radicals, healthy cells can be destroyed.
Doses absorbed by the so-called critical organs after particular
types of radiotherapy determine the  side effects of radiotherapy
when those organs are damaged [9].
The RIT side effects are associated mainly with haematologi-
cal toxicity, being the largest for blood platelets and neutrophiles
[11]. In the case of serious neutropenia, patients can obtain a gran-
ulocyte growth agent; however, its preventive administration be-
fore therapy or in the first several weeks after therapy is not al-
lowed due to the possibility of cell damage induced by irradiation
[11]. Based on their analysis of 349 Zevalin treated patients Witzig
et al. [11] found that 40% of them displayed grade 1–2 neutrope-
nia, while 30% of them displayed grade 3–4. Despite that, the in-
fection proportion was low, and only 7% of patients required hos-
pitalisation. The analyses conducted by those authors demonstrat-
ed that 37% of patients developed mild to medium thrombocy-
topenia, while 63% developed grade 3–4 thrombocytopenia. The
PLT level in 196 patients with grade 3–4 toxicity returned to a value
≥ 50,000/µl within 12 weeks after therapy. Anaemia grade 3 and
grade 4 occurred in 13% and 4% of subjects, respectively. In the
Clayton et al. study, red blood cell level reduction (grade 3–4 toxi-
city) was seen in only 17% of patients [10].
Similarly, in our study the only problem with RIT was haemato-
logical toxicity. Leucopoenia occurred in 27 patients; 3 patients
were free of this side effect. Thrombocytopenia also developed in
27 patients; in 3 patients thrombocytes maintained normal values
after treatment. The period of the occurrence of the lowest values
of blood indices among our patients, despite the small number of
patients in our group, is comparable to the data presented in liter-
ature, similarly to the time of maintenance of lowered PLT, WBC
and ANC values [11]. The decrease of the blood morphology val-
ues started 2–3 weeks after RIT; however, nadir occurred in weeks
7–9. In various groups of lymphomas, we observed a small shift of
that period after administration of Zevalin. The period of close mon-
itoring, due to the possibility of the occurrence of agranulocytosis
and thrombocytopenia, lasted from 1 to 4 weeks (grade 4 toxicity
occurred in 14% and 35% of patients, respectively) [11–13].
Similarly to other reports [10, 11], lower haemoglobin values
were not an essential side effect of radioimmunotherapy.
In order to determine the maximum therapeutic activity, litera-
ture quotes the data concerning the evaluation of the biodistribu-
tion of radiolabelled 111In ibritumomab tiuxetan (111In is a gamma
radiation and Auger electron emitter), using MIRDOSE 3 software.
Based on the results of the respective studies, it was calculated
that the average absorbed doses of radiation for particular organs,
after administration of Zevalin labelled with 90Y at the radioactivity
levels of 15 MBq/kg and 11 MBq/kg, in accordance with the Me-
dical Internal Radiation Dosimetry (MIRD), were as follows: 7.42 Gy
for spleen, 4.5 Gy for liver, 2.11 Gy for lungs, 0.23 Gy for kidneys,
0.62–0.97 for bone marrow and 0.57 for the whole body. Since no
correlation was observed between the dosimetric calculations and
haematological toxicity, the dosimetric results do not have a pre-
dictive value in the area of the Zevalin toxicity, and that is why the
use of dosimetric results is generally not recommended. The esti-
mated doses of radiation absorbed by the healthy organs were
much lower than the generally assumed upper boundary values.
Based on respective studies, it was found that toxicity correlated
with the bone marrow reserves [12]. Nevertheless, that basis was
used to establish the maximum activity of the administered 90Y at
1.184 MBq.
Haematological toxicity did not constitute, in general, a seri-
ous problem in the case of neuroendocrine tumours. However,
among the side effects which may occur after the treatment with
radio-labelled somatostatin analogues is bone marrow suppres-
sion, most often associated with the application of large doses of
radiotherapy (estimated absorbed dose was ca. 3 Gy for bone
marrow). Leucopoenia with granulocytopenia and thrombocytope-
nia in grades III or IV of haematological toxicity occurred relatively
rarely and were usually of a temporary nature [14]. However, even
Figure 5. Average creatinine values in patients with neuroendocrine tu-
mours (NET) and non Hodgkin’s lymphoma (NHL) before and during
4–6 months of treatment.
Figure 6. Proportions of response to treatment in patients with neuroen-
docrine tumours (NET) and non Hodgkin’s lymphoma (NHL). CR — com-
plete response; PR — partial response; PD — progression of disease;
SD — stabilisation of disease.
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when the absorbed dose is lower than the threshold dose for toxic-
ity (mainly in bone marrow), especially in cases of repeated doses,
lesions indicating haematological toxicity can occur. Severe grade
3 and 4 haematological toxicity can occur after the [90Y-DOTA0,
Tyr3] octreotide treatment, and sporadic cases of myeloblastic syn-
drome occur after each of the radionuclides [15]. Most frequently,
however, similarly to our study group, temporary reduction of blood
morphology low indices was observed (grade I and II toxicity) [16].
In the studies by Paganelli et al. [17], among the patients who
obtained a cumulative activity of 90Y-DOTA TOC at a level of 6.66–
–7.77 GBq, 41.7% developed grade 2 haematological toxicity in
leukocytes, but the values returned to normal in all cases within
4–6 weeks. Most toxicity in the range of grade 0–1 occurred in
doses greater than 5.55 GBq; this was the result of a very low dose
being delivered to the bone marrow, as was estimated in dosimet-
ric examinations [18]. In most other published data, reversible hae-
matological toxicity was observed [16, 19, 20]. In the report pre-
sented by Otte et al. [21], no significant haematological toxicity
(£ grade 2 toxicity) was observed in 24 out of 29 patients; after
treatment with a cumulative activity of ≥ 7.4 GBq, 2 out of 5 pa-
tients developed anaemia (grade 3) and thrombocytopenia (grade
4) that required treatment.
In our study group, the majority (59%) displayed a temporary
reduction of blood indices, especially regarding leukocytes. The
WBC values were reduced during subsequent therapies; how-
ever, grade 3 haematological toxicity was seen in only 3 patients.
Grade 1 and 2 toxicities dominated, as in the specific literature,
and were of a temporary nature [14, 16, 17]. Only in one person
were reduced leukocyte counts maintained for several months with-
out any clinical symptoms. The reduced leukocyte counts appeared
several days after the therapy was applied, but between subse-
quent cycles their values came back to levels that allowed further
treatment, similarly to the results of Waldherr et al. [16]. The values
of the remaining indices after the 90Y-DOTA TATE treatment be-
haved similarly, both for blood platelets and haemoglobin, which
were reduced after subsequent therapy cycles, and, similarly to
leukocytes, increasing between subsequent cycles and returning
to the standard boundaries after completion of the treatment. Our
results agree with those available in literature, indicating the tem-
porary nature of the blood morphology changes [14], which could
be the result of a low dose delivered to bone marrow [17].
Toxic renal lesions were not observed as side effects of the ra-
dioimmunotherapy. Based on the results of the dosimetric exami-
nation, it was estimated that the average absorbed dose of radia-
tion in the kidneys amounted to 0.23 Gy (calculated using MIRD
methodology), while Zevalin secretion in urine was limited and dis-
played insignificant differences among the patients. In case of the
NET tumours, the administration of the doses estimated for the tu-
mours could be limited by a high dose absorbed by the kidneys
[18], while the cumulated dose for kidneys exceeding 27 Gy could
become a reason for renal failure. Reduction of renal efficiency may
occur even several days after therapy, which is why, after a period of
patient observation, it is necessary to evaluate renal function for
a longer period after therapy to evaluate the long-term risk of clini-
cally significant renal function deficiency [22]. As a protective action,
amino acid infusions are applied to reduce reabsorption of the radi-
olabelled analogue in proximal canaliculi. A positive charge of argin-
ine and lysine deters reabsorption of the radiolabelled analogue
through renal tubules and its retention by interstitial cells, providing
nephroprotection and allowing the administration of higher radionu-
clide activity [23]. In the study by Otte et al., 5 patients without neph-
roprotection developed toxic renal lesions after treatment with a cu-
mulative activity of ≥ 7.4 GBq. In two of them, stable renal failure
developed, while 2 patients given higher cumulative activities required
haemodialysis. The increase of creatinine levels was still observed
about 2–4 months after the last cycle of treatment.
The study by Jamar et al. [24] demonstrated that 10 hours of
an amino acid mixture infusion gave an increase in nephroprotec-
tion after [86Y-DOTA0-D-Phe1-Tyr3] octreotide treatment.
A similar experience was described in the results of the work by
Rolleman et al. [25]. The studies by Bodei et al. [23] showed the
protective action of arginine and lysine amino acid infusions direct-
ly before and after therapy, with the infusion of various activities of
90Y-DOTATOC up to a total of 5.55 GBq per cycle. Activity of 5 GBq
per cycle is recommended for 90Y-DOTATOC, and amino acids must
be applied for nephroprotection. Brans et al. [15] reported that spo-
radic cases of delayed kidney failure or final stages of the disease
that required haemodialysis were observed especially in patients
who were treated with activity exceeding 7.4 GBq/m2.
In our study group, no essential deterioration of renal func-
tion was observed after treatment. This could be explained by
protective amino acid infusion and the administration of activity
not exceeding 7.4 GBq per patient during the whole treatment
cycle [15, 20, 21, 23, 26]. That in turn allowed the cumulative dose
for kidneys to be kept at levels below 27 Gy [22]. According to
other reports, toxic renal lesions may appear not at the beginning
of observations but later; 2–4 months [20, 21], 5 months [16] and
even several years after the completion of therapy [22, 27]. In our
study group, no kidney failure symptoms occurred with renal func-
tion stabilisation; however, the patients remain under observa-
tion.
Conclusions
1. After treatment with the use of the 90Y radionuclide, no signifi-
cant treatment toxicity, including disorders involving the criti-
cal organs for both types of therapies, was found in the groups
of neuroendocrine tumour and non-Hodgkin's lymphoma pa-
tients.
2. Therapy with the application of 90Y radio-labelled somatostatin
analogues is a well-tolerated method of neuroendocrine tu-
mour treatment, with the possibility of obtaining clinical out-
comes in the form of reduced tumour weight and patient
lifespan prolongation.
3. Zevalin is a safe and effective means of therapy in cases of
relapsed or resistant non-Hodgkin's lymphoma and in cases
of patients with mantle cell lymphoma, influencing the consol-
idation of the chemotherapeutic effect. This allows the prolon-
gation of patient lifespan with the use of non-arduous therapy.
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